NextPharma SAS is a finished-dose manufacturer based in France. It appears in 14 regulatory filings across 4 regulators, without an active US DMF or CEP on file. Its filings concentrate with UZPHARM (UZ), ARCSA (EC) and NPRA (MY). Its GMP standing is certified by ANSM (FR), EMA and ANVISA (Brazil), among 4 authorities. Its most recent recorded inspection, by US FDA, closed on 7 April 2022 as VAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| Finland, Finland | 3016974567 |
| LIMAY, France | Not on file |
| Limay, France | Not on file |
| Santo António dos Cavaleiros, Portugal | Not on file |
| Regulator | Filings | GMP certificates |
|---|---|---|
| UZPHARM (UZ) | 9 | None |
| ARCSA (EC) | 3 | None |
| NPRA (MY) | 1 | None |
| MINSA (CR) | 1 | None |
| ANSM (FR) | None | 5 |
| EMA | None | 2 |
| ANVISA (Brazil) | None | 1 |
| EAEU_EEC | None | 1 |
| Year | Revenue | Exports | Destinations |
|---|---|---|---|
| 2024 | $54.2M | Not reported | Not reported |
Export figures are customs aggregates. We do not publish the identity of any buyer. Revenue shown in US dollars, converted from the reported currency.
Choose your molecules and target markets. NextPharma SAS comes back tiered against every other supplier able to file there.
Start for free